Chiroscience Group Plc was a British-based biotech company, founded by Christopher Evans.

Chiroscience was born from the demise of the company Enzymatix, which was ultimately acquired by Genzyme,[4] when Andrew Richards joined the company and convinced Evans and Peter Keen to launch Chiros, which name was quickly revised to Chrioscience.

[3] Seed funding for the company of £3 million was provided by Schroder Ventures, Apax and 3i.

[3] Chiroscience became one of the first biotechnology Initial Public Offerings in the United Kingdom in 1994.

[2] By the time of its merger with Celltech in 1999,[5] both Chris Evans and Peter Keen had left the company, leaving Andrew Richards as the sole remaining founder and member of the original management board.